ライフサイエンスコーパス: complement factor

1 t attachment analogous to that used by human complement factors.

2 rafiltrate-derived serum proteins, including complement factors.

3 gated specific interactions between IAPP and complement factors.

4 itors alpha(2)-macroglobulins and vertebrate complement factors.

5 anaphylotoxin domain, a central component of complement factors.

6 ibition or from increased local synthesis of complement factors.

7 ) is impaired, despite elevations of certain complement factors.

8 ecially when the virions were opsonized with complement factors.

9 human-inflamed tissue and allows binding of complement factor 1q (C1q) and activation of the classic

10 ient (C1q KO), MBL-A/C-deficient (MBL-null), complement factor 2- and factor B-deficient (C2/fB KO),

11 Complement factor 3 (C3) deficiency causes prolonged ble

12 ion with Complement Factor H (CFH) Y402H and Complement factor 3 (C3) rs2230199 (R102G) in AMD.

13 significantly more opsonized with activated complement factor 3 and membrane attack complex from ser

14 in a very potent downregulation of activated complement factor 3 opsonization on the pathogen surface

15 We identify a nonsynonymous coding change in complement factor 3 that is strongly associated with ris

16 more importantly it also captures activated complement factor 3 within the complex with factor B, th

17 eport that amyloid clearance in mice lacking complement factors 3 and 4 (C3C4(-/-)) was equally effic

18 eficient in mannose-binding lectin (Mbl2) or complement factor 3a receptor (C3aR).

19 thway involved, we studied mice deficient in complement factor 4 (C4-/-), a critical component of the

20 Complement factor 5 (C5) and its cleavage product C5a ar

21 Here, we report that complement factor 5 (C5) contributes significantly to ch

22 naphylatoxins, as mouse strains deficient in complement factor 5 (C5) or the complement receptor C5aR

23 e to a defect in the Hc locus, which encodes complement factor 5 (C5).

24 Levels of complement factor 5/5a were higher in survivors compared

25 Complement factor 5a (C5a) is an anaphylatoxin that acts

26 peptidic ligands is the chemotactic cytokine complement factor 5a (C5a), a 74-amino acid helical bund

27 novel EC3-N terminus cysteine pair into the complement factor 5a receptor (C5aR), a chemo attractant

28 tial residues in the N terminus of the human complement factor 5a receptor (C5aR).

29 generated postvaccination were recognized by complement factors and assisted in killing S.

30 on of dysferlin normalized the expression of complement factors and eliminated the dystrophic phenoty

31 lement activation, but due to promiscuity of complement factors and redundancy of pathways, it is sti

32 Notably, complement factors and their fragments may serve as biom

33 in (apoJ), PLTP itself, coagulation factors, complement factors, and apoA-I.

34 over, upregulation of immediate early genes, complement factors, apoptosis, and immune response genes

35 Complement factors are being considered as targets for t

36 Hence, antibodies or complement factors are not necessary for natural amyloid

37 apoptotic cells activate complement and some complement factors are opsonins for phagocytosis and pla

38 Complement factors are serum proteins that work through

39 assays utilizing sera depleted of individual complement factors as well as adding back purified facto

40 he association of complement component 2(C2)/complement factor B (CFB) gene polymorphisms with age-re

41 ariants in the complement factor H (CFH) and complement factor B (CFB) genes has targeted the search

42 crosis factor alpha (TNF-alpha) induction of complement factor B (CFB) in RPE cells.

43 ned the roles of complement component C3 and complement factor B (CFB) in the growth of cSCC.

44 Complement factor B (cfB) is an essential component of t

45 d to investigate the possible association of Complement Factor B (CFB) rs4151667 (L9H) variants and t

46 on of TLR2, TLR3, and TLR4 markedly enhanced complement factor B (cfB) synthesis and release by macro

47 (ARMS2/HTRA1), complement component 2 (C2), complement factor B (CFB), complement component 3 (C3),

48 We studied 1 of these proinflammatory genes, complement factor B (Cfb), in detail, because complement

49 th rs3736265 and a AMD-associated variant in complement factor B (CFB, rs512559).

50 We hypothesized that circulating levels of complement factor B (FB), an important component of the

51 nt 3 (rs2230199), and complement component 2/complement factor B (rs4151667) were examined using mult

52 e susceptibility to AOM in mice deficient in complement factor B and C2 (Bf/C2(-/)(-)), C1qa (C1qa(-/

53 hibitor impaired the interaction of C3b with complement factor B and, consequently, formation of the

54 on mutation in mice and a mutant form of the complement factor B protein that produces a stable, prop

55 x 10(-47)), C2 (complement component 2)-CFB (complement factor B) (P =5.2 x 10(-9)), C3 (complement c

56 ternative pathway and that mice deficient in complement factor B, an essential component of the alter

57 of mRNAs for CD3epsilon, CD105, TLR4, CD14, complement factor B, and vimentin that distinguishes acu

58 plement component 2, complement component 3, complement factor B, collagen type VIII alpha 1, and RAD

59 c alpha-2 glycoprotein, alpha-1 antitrypsin, complement factor B, haptoglobin, transthyretin, plasma

60 chitinase 3-like protein 1 (CHI3L1), CHI3L2, complement factor B, matrix metalloproteinase 3, ECM-1,

61 ucing a second mutation in the gene encoding complement factor B, which prevents C3 turnover in vivo,

62 ibrinogen, haptoglobin, serum amyloid A, and complement factors (B, C3, and C9).

63 e deposited on TF1PIGAnull target cells, and complement factor Bb is increased in the supernatant fro

64 virions in body fluids can be opsonized with complement factors because of HIV-mediated triggering of

65 Flow cytometry assays were used to assess complement factor binding and complement-dependent neutr

66 subsets is severely hampered in mice lacking complement factor C1q (C1qa(-/-)).

67 ovel approach could also be applied to other complement factor C1q family members; in particular, thi

68 g up-regulation of synapse pruning-promoting complement factor C1q, and down-regulation of Etv1/ER81,

69 lecules, such as the classical FcgammaRs and complement factor C1q, has not been studied in detail.

70 binding to both the classical FcgammaRs and complement factor C1q, which ultimately results in alter

71 ating the expression levels of VEGFD and the complement factor C1q-c, two nuclear calcium-regulated g

72 nediaminetetraacetic acid-treated normal and complement factors C1q, C4/C3, C2, C3, factor B or C5-de

73 We evaluated the role of complement factor C3 (C3) and the murine gamma-herpesvir

74 inflammation-related factors common to TBI: complement factor C3 (C3), glial fibrillary acidic prote

75 e mode of action of the Ab did not depend on complement factor C3 and did not lead to improved Ag pre

76 plement receptors and upon serum with intact complement factor C3 and that uptake requires actin micr

77 t otherwise functional AHR mutant identified complement factor C3 as a potential SAhRM target.

78 t that the classical pathway is required for complement factor C3 deposition on the bacterial surface

79 otein factor H directly, thereby, preventing complement factor C3 deposition on the surface of the ba

80 Complement factor C3 is made in rheumatoid synovium and

81 Complement factor C3 is the central component of the com

82 We examine whether complement factor C3 or C5 is synthesized by human skin-

83 Here we show that the central complement factor C3 secreted from astrocytes interacts

84 ion was independent of natural antibodies or complement factor C3, and instead relied on scavenger re

85 which binds to extracellular fibrinogen and complement factor C3, might partially contribute to bact

86 rall protein fold of TEP1r resembles that of complement factor C3, the TEP1r domains are repositioned

87 erformed with antibodies detecting activated complement factor C3, transferrin receptor, L-ferritin,

88 rs of matrix metalloproteases (TIMPs) and in complement factors C3 and C5.

89 in the RPE, which significantly reduced the complement factors C3/C3b in the RPE.

90 Binding of complement factors C3b, IgM, C1q, mannose-binding lectin

91 mining the human leukocyte antigen (HLA) and complement factor C4 genes and proteins.

92 tivate complement as measured by cleavage of complement factor C4.

93 enes and the complex structural diversity of complement factor C4A/C4B It has also uncovered extensiv

94 determine the prevalence and localization of complement factor C4d in kidneys of patients with TMA.

95 induction therapy, gusperimus, belimumab and complement factor C5a inhibition are also ongoing, and m

96 prediction for thermostable mutations of the complement factor C5a receptor 1 retrieved 36% of the th

97 Complement factor C5a slightly increases the expression

98 neutrophil recruitment and activation is the complement factor C5a, which signals through two recepto

99 The chemotactic response to the complement factors C5a and C3a is ablated in cells lacki

100 cells (HUVECs) by real-time PCR: C3 and C5; complement factor (CF) B, CFD, CFP, CFH and CFI of the A

101 hich can be explained by decreased levels of complement factor D (CFD) and C7 components of the compl

102 It had been thought that complement factor D (FD) is activated at the site of syn

103 Complement factor D (FD), a highly specific S1 serine pr

104 The adipokine adipsin/complement factor D controls the alternative complement

105 ion in the presence of eculizumab or control complement factor D inhibitor ACH-4471, which blocks the

106 ase inhibitors, was originally designed as a complement factor D inhibitor and exhibited submicromola

107 Validation of 4 PVAN-specific genes (RPS15, complement factor D, lactotransferrin, and nitric oxide

108 Analysis of complement factors does not reveal any changes that are

109 t specificity and differential expression of complement factors, ECM proteins and osteogenic genes.

110 Ligands include the complement factor fragment iC3b, a key component in the

111 Genetic risk was based on Y402H in complement factor H (CFH) and A69S in age-related maculo

112 ants were genotyped for polymorphisms in the complement factor H (CFH) and age-related maculopathy su

113 cleotide polymorphisms were genotyped in the complement factor H (CFH) and ARMS2 genes using a Taqman

114 Two biologically related factors, complement factor H (CFH) and C-reactive protein (CRP),

115 the relationship between local (ie, ocular) complement factor H (CFH) and choroidal neovascularizati

116 Association of variants in the complement factor H (CFH) and complement factor B (CFB)

117 tion cluster at chromosome 1q32 contains the complement factor H (CFH) and five complement factor H-r

118 s study, we investigated the associations of complement factor H (CFH) and hemicentin-1 (HMCN1) with

119 express various complement factors including complement factor H (CFH) and to promote the removal of

120 Mice deficient in complement factor H (CFH) are a classic C3G model, with

121 ctivation and genetic variants in inhibitory complement factor H (CFH) are also features of both ARMD

122 Adamts13 (-/-) or a heterozygous mutation of complement factor H (cfh) at amino acid residue of 1206

123 In addition, to determine the regulation of complement factor H (CFH) by oxidative stress, in vitro

124 Genetic variations in complement factor H (CFH) confer greater risk for age-re

125 f this disease, identifying mutations in the complement factor H (CFH) gene and a locus on chromosome

126 Rare variants in the complement factor H (CFH) gene and their association wit

127 anding puzzle why non-coding variants in the complement factor H (CFH) gene are more strongly associa

128 Variations in the complement factor H (CFH) gene are tightly associated wi

129 S, with a focus on genetic variations in the complement Factor H (CFH) gene cluster and CFH autoantib

130 us carriers of the Y402H risk variant in the complement factor H (CFH) gene developed neovascular AMD

131 ransition at amino acid position 402) in the complement factor H (CFH) gene have a pharmacogenetics e

132 ty variants and protective haplotypes in the complement factor H (CFH) gene modulate risk for AMD.

133 mparted by carrying the Y402H variant in the complement factor H (CFH) gene on chromosome 1, recent e

134 on of a rare, high-penetrance variant in the complement factor H (CFH) gene that is also causally ass

135 Polymorphisms in the complement factor H (CFH) gene that reduce activity of C

136 A Tyr402His variant in exon 9 in the complement factor H (CFH) gene was also significantly as

137 A locus on chromosome 1q31.1 containing the complement factor H (CFH) gene was strongly associated w

138 inly been attributed to a risk allele in the complement factor H (CFH) gene.

139 underwent Sanger sequencing analysis of the complement factor H (CFH) gene.

140 ted maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) genotypes, and other factors,

141 Complement factor H (CFH) has recently been identified a

142 gh interaction with an SNP (rs380390) in the complement factor H (CFH) intron reported to be highly a

143 Complement factor H (CFH) is a central regulator of the

144 Complement factor H (CFH) is a component of the mammalia

145 Complement factor H (Cfh) is a key plasma protein in hum

146 Complement factor H (CfH) is a key regulator of the alte

147 Complement factor H (Cfh) is a key regulator of the alte

148 Complement factor H (CFH) is a major susceptibility gene

149 Complement factor H (CFH) is a negative regulator of the

150 Plasma complement factor H (Cfh) is a potent complement regulat

151 Complement factor H (CFH) is an important regulatory pro

152 Y402H and I62V substitutions in the gene for complement factor H (CFH) is strongly associated with ri

153 associated loci and 6 additional SNPs at the complement factor H (CFH) locus.

154 eptor 1 (CR1) on human erythrocytes (Es) and complement factor H (CFH) on rodent platelets perform im

155 This activation is efficiently suppressed by complement factor H (CFH) on self-surfaces but not on fo

156 smoking, and presence of risk alleles of the complement factor H (CFH) or age-related maculopathy sus

157 plicated in the disease pathology, including complement factor H (CFH) precursor and alpha-2-macroglo

158 Complement factor H (CFH) regulates complement activatio

159 erage of 10.1 years, individuals with 1 or 2 complement factor H (CFH) risk alleles derived maximum b

160 hyperopia, and AMD-susceptibility genotypes Complement Factor H (CFH) RS1061170 and Age Related Macu

161 Two loci in complement factor H (CFH) were included in a risk score

162 have associated a common variant (Y402H) of complement factor H (CFH) with a highly significant incr

163 variants and their possible interaction with Complement Factor H (CFH) Y402H and Complement factor 3

164 tomegalovirus (CMV) immunoglobulin (Ig)G and complement factor H (CFH) Y402H genotype.

165 Molecular defects in complement factor H (CFH), a critical regulatory protein

166 Genetic variants within complement factor H (CFH), a major alternative complemen

167 These include complement factor H (CFH), a negative regulator of C3 ac

168 Ten genetic loci in 7 genes [complement factor H (CFH), age-related maculopathy susce

169 mplementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the

170 y complement fluid-phase regulatory protein, complement factor H (CFH), are strongly associated with

171 Genetic variants of complement factor H (CFH), C3, C2, and FB associated wit

172 ilies were filtered for rare variants in the complement factor H (CFH), complement factor I (CFI), co

173 Genetic variation across the genes encoding complement factor H (CFH), factor B (CFB) and component

174 with the physiological complement inhibitor, complement factor H (CFH), for ligand binding.

175 sm, encoding the sequence variation Y402H in complement factor H (CFH), has been strongly associated

176 Variants of the CFH gene, encoding complement factor H (CFH), show strong association with

177 rsons with the protective genetic alleles of complement factor H (CFH), the Mediterranean diet had fu

178 Two common variants in the gene encoding complement factor H (CFH), the Y402H substitution (rs106

179 that binds the negative complement regulator complement factor H (CFH), thereby inhibiting the altern

180 ponses by hijacking a host-immune regulator, complement factor H (CFH), to the bacterial surface.

181 ly it to a comparison of hemopexin (HPX) and complement factor H (CFH), two liver-secreted glycoprote

182 Complement factor H (CFH), which inhibits complement act

183 ificant peak was found on chromosome 1, near complement factor H (CFH), with P= 6.20 x 10(-4).

184 th age, sex, smoking status, presence of the complement factor H (CFH)-rs1061170 and age-related macu

185 ted maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH).

186 ANGPT1) and four retinal genes interact with Complement Factor H (CFH).

187 oth common and rare, in the coding region of complement factor H (CFH).

188 omplement proteins or autoantibodies against complement factor H (CFH).

189 or age-related macular degeneration (AMD) is complement factor H (CFH); however, its impact on AMD pa

190 her [age-related macular degeneration (AMD); complement factor H (CFH)], or even three disease charac

191 ts at the chromosome 1q31.3 encompassing the complement factor H (CFH, FH) and CFH related genes (CFH

192 Further, we show that complement factor H (FH) binds mCRP to dampen its proinf

193 The ability to recruit complement factor H (FH) by S. pneumoniae has been impli

194 plement control protein (CCP) modules within complement factor H (fH) encompass binding sites for C3b

195 iC3b, and C3dg and enhanced competition with complement factor H (FH) in surface plasmon resonance (S

196 Complement factor H (FH) inhibits complement activation

197 Complement factor H (fH) is a plasma protein that regula

198 The complement factor H (FH) mutation R1210C, which was desc

199 Numerous complement factor H (FH) mutations predispose patients t

200 histidine (Y402H), within the gene encoding complement factor H (FH) predisposes individuals to acqu

201 The Tyr402His polymorphism of complement factor H (FH) with 20 short complement regula

202 soluble plasma-regulatory proteins including complement factor H (fH), a 155 kDa protein composed of

203 ement-mediated innate immunity by recruiting complement factor H (FH), a complement alternative pathw

204 Complement factor H (fH), a molecule that downregulates

205 cases it is associated with polymorphisms of complement factor H (FH), implicating immune vulnerabili

206 human secretory immunoglobulin A (sIgA) and complement factor H (FH).

207 ve regulator of the AP is the plasma protein complement factor H (FH).

208 Alternative pathway activity is inhibited by complement factor H (FH).

209 und in locus 1q31.3, containing the gene for complement factor H (lead single nucleotide polymorphism

210 is revealed a novel heterozygous mutation in complement factor H (R83S) in addition to known risk pol

211 Interactions with complement factor H (rs1061170), age-related maculopathy

212 Deficiency of complement factor H and mutations in CFH associate with

213 In mice deficient in complement factor H and transgenic for human CR1, solubl

214 d with genetic complement abnormalities/anti-complement factor H antibodies, which paved the way to t

215 ns extend freely into solution when the five complement factor H domains are bound within C3b.

216 MD (P = .03); between rs2669845 and Y402H in complement factor H for AMD (P = .04); and between rs266

217 Polymorphisms in the complement factor H gene (CFH) are associated with a sig

218 typed, an intronic and common variant in the complement factor H gene (CFH) is strongly associated wi

219 actors--smoking and the Y402H variant of the complement factor H gene (CFH)--we used logistic regress

220 a contiguous 358 kb region that contains the Complement Factor H gene cluster.

221 tion studies have found variation within the complement factor H gene family links to host susceptibi

222 Inherited variation in the complement factor H gene is a major risk factor for drus

223 kely caused by the Y402H polymorphism in the complement factor H gene is a recognized risk factor for

224 T-->C substitution in exon 9 (Y402H) of the complement factor H gene is strongly associated with sus

225 age, sex, and the Y402H polymorphism in the complement factor H gene on chromosome 1q) and mortality

226 DNA resequencing of the complement factor H gene within this haplotype revealed

227 Complement factor H genotype had no effect on the respon

228 Deficiency of complement factor H has long been associated with MPGN.

229 iated with host iron availability and higher complement factor H levels, lower expression of gametocy

230 etic mutation causing aHUS, including 4 with complement factor H mutations.

231 The complement factor H R1210C rare variant confers the stro

232 The typical phenotype of the complement factor H R1210C rare variant is associated wi

233 tients carrying a genetic abnormality in the complement factor H related 1 gene (CFHR1) that originat

234 The role of complement factor H still needs to be better defined, bu

235 d, followed by the first five SCR domains of complement factor H that bind to complement C3b.

236 leukin-6 (IL-6), interleukin-10 (IL-10), and complement factor H was unaffected.

237 Maculopathy Susceptibility 2 rs10490924 and Complement Factor H Y402H (P for trend = 4.2x10(-7)).

238 serine peptidase 1) (P =2.7 x 10(-72)), CFH (complement factor H) (P =2.3 x 10(-47)), C2 (complement

239 Genetic investigations have shown that complement factor H, a regulator of the alternative comp

240 Ten loci in 7 AMD genes [complement factor H, age-related maculopathy susceptibil

241 Human complement factor H, consisting of 20 complement control

242 n up to 50% of cases, caused by mutations in complement factor H, membrane cofactor protein, factor I

243 fluid-phase CRP to six immobilized proteins: complement factor H, oxidized low-density lipoprotein, c

244 riants suggest decreased inhibition of C3 by complement factor H, resulting in increased activation o

245 noncoding variant in CFH, the gene encoding complement factor H, that substantially increases the in

246 with these diseases affect the glycoprotein complement factor H, the main regulator of the alternati

247 are disrupted by the abundant serum protein, complement Factor H, thereby probably limiting SIBLING-m

248 characteristic of sub-RPE deposits, such as complement factor H, vitronectin, and amyloid beta, reve

249 a-2-glycoprotein and positively with afamin, complement factor H, VLDL-associated apolipoproteins, an

250 venger receptors, IgM natural antibodies and complement factor H, which bind, neutralize and/or facil

251 association of ARM with the Y402H allele of complement factor H, which has previously been reported

252 e mutant also had decreased binding of human complement Factor H, which in previous studies increased

253 convalescent B1b cell-derived IgM recognizes complement factor H-binding protein (FhbA), a B. hermsii

254 model of MPGN that develops spontaneously in complement factor H-deficient mice (Cfh(-/-)).

255 Copy number variations in the complement factor H-related (CFHR) gene cluster on chrom

256 and identified a chromosomal deletion in the complement factor H-related (CFHR) gene cluster.

257 The autoimmune renal disease deficient for complement factor H-related (CFHR) genes and autoantibod

258 tains the complement factor H (CFH) and five complement factor H-related (CFHR) genes.

259 n includes genomic rearrangements within the complement factor H-related (CFHR) locus.

260 The role of the complement factor H-related (FHR) proteins in homeostasi

261 C3G-associated genomic mutation in the gene complement factor H-related 1 (CFHR1), which encodes FHR

262 onstrates that a duplication within the gene complement factor H-related 1 (CFHR1; encoding FHR1) lea

263 The human complement Factor H-related 5 protein (FHR5) antagonizes

264 ociation studies have shown that deletion of complement factor H-related genes 1 and 3 (CFHR3,1Delta)

265 e association studies identified deletion of complement factor H-related genes 1 and 3 as protective

266 Human complement factor H-related protein (CFHR) 4 belongs to

267 ing the association of rs7517126 with plasma complement factor H-related protein 1 (CFHR1) level at p

268 , Factor H, Factor H-like protein-1 (FHL-1), complement Factor H-related protein 1 (CFHR1), and plasm

269 and endogenous nitric oxide production) and complement factor H-related protein 2 (CFHR2, related to

270 e cosegregated with the same mutation in the complement factor H-related protein 5 gene (CFHR5).

271 Complement factor H-related proteins (FHRs) are strongly

272 the complement cascade C1q, C6, and C8; and complement factor H.

273 ble proteins, such as C-reactive protein and complement factor H.

274 most common mutation is in the gene encoding complement factor H.

275 02 protein polymorphism in the gene encoding complement factor H.

276 ed, i.e., TSG-6, chemokines IL-8 and KC, and complement factor H.

277 Genetic risk factors such as variations in complement factors H (CFH) and B (CFB) have been implica

278 The association of variants in complement factors H and B with age-related macular dege

279 g two host-derived fluid-phase regulators of complement, factor H and factor H-like protein 1 (FHL-1)

280 We demonstrate that complement factor-H related 3 (CFHR3) promotes immune ac

281 e variants in the complement factor H (CFH), complement factor I (CFI), complement C9 (C9), and compl

282 Complement factor I (fI) plays a major role in the regul

283 Both of these proteins act as co-factors for complement factor I (IF).

284 macular degeneration (AMD), we sequenced the complement factor I gene (CFI) in 2266 individuals with

285 use model with combined deficiency of FH and complement factor I, CR2-FH prevented de novo C3 deposit

286 Importantly, cell adhesion to the complement factor iC3b is also diminished, and COS cells

287 including members of the ICAM family and the complement factor iC3b.

288 in deficiency led to increased expression of complement factors in muscle, while muscle-specific tran

289 eports that mechanistically implicated early complement factors in neurodegeneration.

290 2 diabetic patients revealed the presence of complement factors in the islets and varying degree of c

291 Podocytes are known to express various complement factors including complement factor H (CFH) a

292 w restriction-induced venous thrombosis that complement factors make distinct contributions to platel

293 n of Igs, pattern recognition molecules, and complement factors on CC in human plasma.

294 Deposition of complement factors (opsonization) on nanoparticles may p

295 e of pathogens and toxins without activating complement factors or coagulation.

296 Serum immunoglobulins and complement factors, peripheral blood lymphocyte subpopul

297 s and identified a tumor suppressive role of complement factor properdin (CFP) in vitro and in vivo.

298 mannose-binding lectin, which are both early complement factors that tag ACs for innate immune recogn

299 iV) include exposure to environments rich in complement factors, we tested the in vitro sensitivity o

300 ibiting drusen proteins and inflammatory and complement factors while upregulating nucleosome, riboso